Inclusion Criteria:  Children aged 1 to 15 years old :  With acute lymphoblastic leukemia undergoing chemotherapy (at least 2 weeks from the last injection of PEG-asparaginase) or for whom the last chemotherapy is less than or equal to 12 months With acute myeloid leukemia within 12 months from the end of treatment Healthy siblings aged 12 to 15 years old living in the same household than the child with AL more than 50% of the time Informed consent from parents Patient affiliated to health insurance  Exclusion Criteria:  Documented SARS-CoV-2 infection ongoing or that occurred less than 3 months ago Known clinical allergy to polyethylene glycol (PEG) Pregnant woman during first pregnancy quarter or lactating woman Platelet <50 Giga(G) G/L or neutrophils <0.5 G/L at time of vaccination Vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection Any hemorrhagic trouble considered as a contraindication to intramuscular injection History of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component Participant vaccinated against tuberculosis within the past year